Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/S0929-693X(12)71272-1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Geographical and temporal variations of serogroups and clonal types of involved in culture-confirmed invasive meningococcal disease in Canada, 2015-2023.
J Med Microbiol
March 2025
Vaccine Preventable Bacterial Diseases, Science, Reference and Surveillance Directorate, National Microbiology Laboratory Branch, Pubic Health Agency of Canada, Winnipeg, Manitoba, Canada.
Invasive meningococcal disease (IMD) is a nationally notifiable illness in Canada due to its potential severity and transmissibility. Vaccination strategies differ by province/territory and are informed by changes in the antigenic characteristics of circulating strains. Though IMD statistics are tracked at a provincial/territorial level, there is a lack of published data characterizing trends in the epidemiology of this disease at a national level.
View Article and Find Full Text PDFGenetically distinct Hajj and South American-related strains of serogroup W Neisseria meningitidis causing invasive meningococcal disease in Ontario, Canada, January 1, 2015 to June 30, 2024.
J Infect Public Health
March 2025
Vaccine Preventable Bacterial Diseases, National Microbiology Laboratory Branch, Public Health Agency of Canada, Winnipeg, Manitoba, Canada. Electronic address:
Objectives: To characterize the recent trends in serogroup W isolates from invasive meningococcal disease (IMD) cases (MenW) in Ontario, Canada since 2015.
Methods: IMD case isolates in Ontario between January 1, 2015 and June 30, 2024 were examined by phenotypic and genetic methods for possession of vaccine antigen genes and clonal characteristics. MenW ST-11 clonal complex (CC) strains were compared against global MenW isolates by core-genome multi-locus sequence typing (cgMLST).
Assessing the impact of revising MenACWY vaccination schedule for adolescents in the United States: a modelling study.
Lancet Reg Health Am
April 2025
Agent-Based Modelling Laboratory, York University, Toronto, Ontario, Canada.
Background: The current recommendation for MenACWY vaccination against invasive meningococcal disease (IMD) in the United States (US) includes two doses: the first dose at ages 11-12 and a booster dose at age 16. The Advisory Committee on Immunization Practices has proposed options for revising this schedule by either eliminating the first dose or adjusting the timing of the first dose to age 15 and the booster to ages 17-18. The impact of these alternative schedules on IMD incidence remains undetermined.
View Article and Find Full Text PDFIdentification of immunogenic outer membrane vesicle vaccine antigen components using a meningococcal protein microarray.
Vaccine
March 2025
School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK. Electronic address:
Outer membrane vesicle (OMV)-based vaccines have been employed worldwide in response to epidemic meningococcal disease outbreaks caused by Neisseria meningitidis. The complex composition of OMVs raises challenges in the identification of antigens which contribute to a protective immune response. Here, we measured total IgG antibody binding profiles to a dedicated antigen microarray using human sera from an open-label Phase II trial (NCT00962624) of 4CMenB (Bexsero), a licensed vaccine containing an OMV component.
View Article and Find Full Text PDFImmunogenicity and reactogenicity of a booster dose of a typhoid conjugate vaccine (TCV) in Malawian pre-school children.
EClinicalMedicine
March 2025
Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, United States.
Background: We assessed persistence of typhoid immunity conferred by Vi polysaccharide-tetanus toxoid (Vi-TT) conjugate vaccine (TCV) four years post-vaccination and immunogenicity of a booster dose of Vi-TT given at age five.
Methods: In 2018, a phase 3 trial of Vi-TT in Malawi randomised children 1:1 to receive Vi-TT or meningococcal capsular group A conjugate vaccine (control). Subsequently, TCV was licensed and recommended in the region.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!